Comparative efficacy of saxagliptin combination therapy with acarbose, or gliclazide modified release, or metformin in drug naive patients with type 2 diabetes
单位：[1]China–Japan Friendship Hospital, Beijing, China[2]China Meitan General Hospital, Beijing, China[3]The First Affiliated Hospital of Harbin Medical University, Harbin, China[4]Qilu Hospital of Shandong University, Jinan, China[5]Nanjing First Hospital Affiliated to Nanjing Medical University, Nanjing, China[6]The First Affiliated Hospital of Anhui Medical University, Hefei, China[7]The Second Hospital of Anhui Medical University, Hefei, China[8]Tulane University, New Orleans, USA.
第一作者单位：[1]China–Japan Friendship Hospital, Beijing, China
推荐引用方式(GB/T 7714)：
Chen X. P.,Li H. M.,Kuang H. Y.,et al.Comparative efficacy of saxagliptin combination therapy with acarbose, or gliclazide modified release, or metformin in drug naive patients with type 2 diabetes[J].DIABETOLOGIA.2018,61:S377-S377.
APA：
Chen, X. P.,Li, H. M.,Kuang, H. Y.,Chen, L.,Ma, J. H....&Yang, W. Y..(2018).Comparative efficacy of saxagliptin combination therapy with acarbose, or gliclazide modified release, or metformin in drug naive patients with type 2 diabetes.DIABETOLOGIA,61,
MLA：
Chen, X. P.,et al."Comparative efficacy of saxagliptin combination therapy with acarbose, or gliclazide modified release, or metformin in drug naive patients with type 2 diabetes".DIABETOLOGIA 61.(2018):S377-S377
医学